...
CIPM 2026 Q&A cover: pellet and 3-in-1 granulation at JIANPAI booth
CIPM 2026 : questions-réponses sur la granulation centrifuge et l’extrusion, et le granulateur 3-en-1
From October 27 to 29, 2026, the 68th China National Pharmaceutical Machinery Expo (CIPM 2026) filled...
CIPM 2026 Q&A cover: smart OSD, mixing and coating at JIANPAI booth 2-B27
CIPM 2026 : questions-réponses sur la fabrication OSD intelligente, le mélange triple excentrique et l’enrobage
At CIPM 2026 in Xiamen (October 27-29, 2026), visitors to JIANPAI Booth 2-B27 did not ask for brochures....
JianPai Technology team at CIPM 2026 Xiamen
JianPai Technology clôture avec succès sa participation au CIPM 2026 à Xiamen
JianPai Technology wraps up CIPM 2026 Xiamen at Booth 2-B27 (Oct 27–29): fluid bed and high-shear granulators,...
Top generic pharma manufacturing companies in Indonesia 2026 B2B shortlist cover with JIANPAI fluid bed equipment
Principaux fabricants de génériques en Indonésie : shortlist B2B 2026
Indonesia’s generics market is shaped by BPOM licensing, CPOB (GMP) expectations, and JKN / e-catalogue...

À PROPOS DE NOUS

À propos de nous - Présentation de notre équipe,
mission et valeurs.

Classement 2026 des 50 plus grands laboratoires pharmaceutiques

Classement 2026 des 50 plus grands laboratoires pharmaceutiques

The global pharmaceutical industry continues to experience strong growth driven by innovation in biologics, oncology, diabetes and obesity treatment, vaccines, and rare disease therapies. In August 2026, Pharm Exec magazine published the 2026 Pharm Exec 50, ranking the Top 50 pharmaceutical companies worldwide by prescription drug (Rx) sales in fiscal year 2025.

This ranking is widely regarded as one of the most authoritative industry benchmarks, offering valuable insight for pharmaceutical manufacturers, API and packaging suppliers, pharmaceutical equipment companies, and distributors and contract manufacturing organizations (CMOs).

Below is the fully updated 2026 Global Top 50 Pharmaceutical Companies List, based on 2025 Rx sales.

Méthodologie de classement

  • Source du classement : Pharm Exec magazine (2026 Pharm Exec 50, published August 14, 2026)
  • Base de classement : Global prescription drug (Rx) sales
  • Exercice fiscal: 2025
  • Année de publication du classement : 2026

Ce classement reflète une réelle performance commerciale, not market capitalization or valuation. Figures in the table are 2025 Rx sales, shown in US$ billion.

2026 Global Top 50 Pharmaceutical Companies (Complete List)

Rang Entreprise Quartier général 2025 Rx sales (US$ billion)
1 Elie Lilly USA 60.78
2 Johnson & Johnson USA 59.33
3 AbbVie USA 58.27
4 Roche Suisse 57.51
5 AstraZeneca ROYAUME-UNI 55.04
6 Merck & Co. (MSD) USA 54.69
7 Novartis Suisse 54.33
8 Pfizer USA 49.91
9 Sanofi France 48.97
10 Bristol Myers Squibb USA 47.75
11 Novo Nordisk Danemark 46.80
12 GSK (GlaxoSmithKline) ROYAUME-UNI 42.72
13 Amgen USA 34.95
14 Takeda Japon 29.67
15 Sciences de Galaad USA 28.83
16 Boehringer Ingelheim Allemagne 23.82
17 Bayer Allemagne 19.19
18 CSL Australie 15.44
19 Viatris USA 14.09
20 Téva Israël 14.08
21 Astellas Japon 12.60
22 Daiichi Sankyo Japon 12.04
23 Produits pharmaceutiques Vertex USA 11.97
24 Groupe Sandoz Suisse 11.09
25 Otsuka Holdings Japon 9.87
26 Merck KGaA Allemagne 9.73
27 UCB Belgique 8.24
28 Grifols Espagne 7.33
29 Biogène USA 7.12
30 Sun Pharma Inde 6.44
31 Régénéron USA 6.31
32 Organon USA 6.06
33 Yunnan Baiyao Chine 5.72
34 Abbott USA 5.51
35 Servier France 5.44
36 Bausch Health Canada 5.41
37 BeOne Medicines (formerly BeiGene) Suisse 5.28
38 Fresenius Allemagne 5.21
39 Shanghai Pharmaceuticals Chine 5.16
40 Eisaï Japon 4.78
41 Sino Biopharmaceutical Hong Kong 4.37
42 Ménarini Italie 4.36
43 Incyte USA 4.35
44 Ipsen France 4.16
45 argenx Pays-Bas 4.15
46 Jazz Pharmaceutique Irlande 4.02
47 STADA Allemagne 4.02
48 Médecine Huadong Chine 3.97
49 Médecine Jiangsu Hengrui Chine 3.85
50 Haleon ROYAUME-UNI 3.60

Data source: Pharm Exec, 2026 Pharm Exec 50 (FY 2025 prescription drug sales). Company names use common English forms; BeOne Medicines appears under its current name (formerly BeiGene).

Key Industry Trends from the 2026 Ranking

1. Eli Lilly Rises to No. 1

The headline change this year is Eli Lilly’s jump from No. 11 in the previous ranking to No. 1, with about $60.8 billion in 2025 Rx sales, up roughly 49% year over year. Johnson & Johnson, last year’s leader, is now No. 2. AbbVie, Roche, and AstraZeneca complete the top five.

2. U.S. Companies Continue to Lead by Count

Fifteen companies in the Top 50 are headquartered in the United States, still the largest national group, with particular strength in oncology, immunology, biologics, and metabolic disease, including GLP-1 therapies.

3. Switzerland, Japan, and Germany Remain Innovation Hubs

Switzerland is represented by Roche, Novartis, Sandoz, and BeOne Medicines (formerly BeiGene, now listed with a Swiss headquarters). Japan remains well represented by Takeda, Astellas, Daiichi Sankyo, Otsuka, and Eisai. Germany includes Boehringer Ingelheim, Bayer, Merck KGaA, Fresenius, and STADA.

4. China Holds Five Places; India Is Represented by Sun Pharma

Five Chinese companies are in this year’s list if Sino Biopharmaceutical (Hong Kong) is included: Yunnan Baiyao, Shanghai Pharmaceuticals (a new entrant), Sino Biopharmaceutical, Huadong Medicine, and Jiangsu Hengrui Medicine. CSPC Pharmaceutical Group is no longer in the Top 50. From India, Sun Pharma remains on the list; Dr. Reddy’s Laboratories is not in this year’s Top 50. New global entrants also include argenx (Netherlands) and Haleon (UK).

Pourquoi ce classement est important pour les fournisseurs de produits pharmaceutiques

If you are involved in pharmaceutical machinery manufacturing, packaging solutions (vials, bottles, blister, ampoules), API and excipient supply, or contract manufacturing (CDMO/CMO), this list directly reflects where purchasing power is concentrated, which companies control global drug production, and who your most valuable long-term customers may be.

Outlook for the Global Pharmaceutical Industry in 2026

Based on this ranking, the pharmaceutical industry will continue focusing on biologics and biosimilars, GLP-1 diabetes and obesity drugs, cancer immunotherapy, rare disease treatments, and personalized medicine. Companies at the top of the 2026 Pharm Exec 50 are expected to drive mergers and acquisitions, equipment upgrades, and new plant investments worldwide.

Quel équipement ces leaders pharmaceutiques utilisent-ils ?

La plupart des entreprises de ce classement mènent de grandes opérations de dosage oral solide (OSD) parallèlement aux produits biologiques. Leurs usines de comprimés et de capsules sont construites autour d'une chaîne de processus similaire, et chaque étape nécessite un équipement de qualité GMP qui produit des lots reproductibles. Nous couvrons cela en détail dans quel équipement les 50 plus grandes sociétés pharmaceutiques mondiales utilisent-elles pour garantir la qualité.

Étape du processus But Équipements JIANPAI associés
Granulation humide Densifier les poudres et améliorer l’uniformité du flux et du contenu Granulateurs mélangeurs à haut cisaillement (JHZ-C, JHZ-D)
Séchage Réduire l'humidité des granulés au niveau validé Sécheurs à lit fluidisé (JFG-C)
Dimensionnement et fraisage Contrôler la taille des particules avant de mélanger Usines pharmaceutiques (Granulateur de dimensionnement JZL)
Mélange Mélanger les granulés avec des lubrifiants et des excipients Mélangeurs pharmaceutiques (Mélangeur à trois excentricités JPH)
Revêtement Film, sucre ou enrobage entérique des comprimés Machines à enrober les comprimés (JGB-D, JGB-E)
Lignes intégrées Lignes de granulation fermées et reliées qui réduisent la manipulation manuelle Ligne de production de granulation totalement fermée, fabrication continue

Les fabricants de génériques et sous contrat qui approvisionnent ces leaders, ou qui sont en concurrence avec eux, comparent souvent leurs propres gammes aux mêmes normes. Pour la planification budgétaire, consultez notre guide des prix des machines de revêtement de comprimés.

Conclusion

Le 2026 Global Top 50 Pharmaceutical Companies Ranking provides a clear overview of the world’s leading drug manufacturers, based on 2025 prescription drug sales, and reflects the direction of the global pharmaceutical industry. From biologics and oncology to diabetes, obesity, and rare disease therapies, these top companies will continue to drive innovation, capacity expansion, and equipment upgrades worldwide.

En tant que fabricant professionnel de machines pharmaceutiques, Jianpai closely follows the development trends of these global pharma leaders and is committed to providing reliable, high-efficiency production and processing solutions for pharmaceutical manufacturers across the world. Whether you are planning a new production line, upgrading existing equipment, or expanding your formulation and packaging capacity, JIANPAI offers customized solutions to meet your exact needs.

FAQ

Who is the largest pharmaceutical company in the 2026 ranking?

Eli Lilly is No. 1 in the 2026 Pharm Exec 50, with about $60.8 billion in 2025 prescription (Rx) drug sales. Johnson & Johnson is No. 2. The complete Top 50 table above ranks companies by 2025 Rx sales, as described in the methodology section.

What equipment do top pharmaceutical companies use for oral solid dosage?

Large OSD plants typically run high shear wet granulation, fluid bed drying, milling and sizing, blending, tablet compression, and film or functional coating, often with closed material transfer and automated cleaning.

Why does this ranking matter for equipment suppliers?

Top companies set the quality and compliance expectations that generic and contract manufacturers follow. Equipment that meets their GMP, data integrity and containment needs is increasingly expected across the industry.

Vous envisagez une ligne OSD conforme aux normes mondiales ?

JIANPAI fournit des équipements de granulation, de séchage, de broyage, de mélange et d'enrobage pour les usines de dosage oral solide. Envoyez-nous vos produits et votre capacité cible pour une proposition de ligne.

E-mail: [email protected] | Tél : +86 577-86932456 | No. 989 Lingde Road, nouveau district d'Oujiangkou, Wenzhou, Zhejiang, Chine

fr_FRFR

Dites-nous votre Exigences Questions Besoins Idées Plans